Impact of obesity on oxalate production related to kidney stones
Influence of Obesity on Endogenous Oxalate Synthesis
This study is trying to see how being obese affects the body’s production of oxalate, which can lead to kidney stones, by comparing people with different weights on a special diet.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 40 (estimated) |
| Ages | 18 Years to 60 Years |
| Sex | All |
| Sponsor | University of Alabama at Birmingham Academic / other |
| Locations | 1 site (Birmingham, Alabama) |
| Trial ID | NCT03704350 on ClinicalTrials.gov |
What this trial studies
This study investigates how obesity influences the synthesis of oxalate, a key factor in the formation of kidney stones. Participants aged 25-60 with a BMI under 50 will follow a controlled low oxalate diet to measure endogenous oxalate production. By comparing non-obese and obese individuals who have not previously formed kidney stones, the study aims to clarify the relationship between obesity and urinary oxalate levels. The findings could lead to new strategies for preventing kidney stones, which are a significant health concern.
Who should consider this trial
Good fit: Ideal candidates are adults aged 25-60 with a BMI under 50 who have no history of kidney stones.
Not a fit: Patients with a history of kidney stones or other significant health conditions such as diabetes or chronic kidney disease may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved prevention strategies for kidney stones in obese individuals.
How similar studies have performed: While there is evidence linking obesity to kidney stones, this specific approach of controlled dietary intervention to study endogenous oxalate synthesis is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age 25-60 years * Body Mass Index (BMI) \<50 Exclusion Criteria: * history of kidney stones * history of diabetes, hepatic disease, renal disease including Chronic Kidney Disease (CKD), bowel disease or other endocrine disorders * pregnant or lactating women, or those with the intention to become pregnant in the near future * abnormal liver enzymes * hemoglobin A1C \> 6.5
Where this trial is running
Birmingham, Alabama
- University of Alabama at Birmingham — Birmingham, Alabama, United States (Recruiting)
Study contacts
- Principal investigator: Dean Assimos, MD — University of Alabama at Birmingham
- Study coordinator: Sonia Fargue, MD PhD
- Email: sfargue@uab.edu
- Phone: 205-934-0169
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.